Q32 Bio entered into an underwriting agreement to sell 6,027,399 common shares at $18.25 and pre-funded warrants for 4,931,506 shares at $18.2499. Underwriters have a 30-day option to purchase up to 1,643,835 additional shares. Net proceeds are expected to be approximately $187.6 million, or $215.8 million if the option is fully exercised. The company plans to use proceeds for working capital, R&D, clinical development, and advancing bempikibart.
Agreement details:
- Agreement type: Underwriting agreement for public offering of common stock and pre-funded warrants
- Counterparty: Morgan Stanley, Jefferies, Cantor Fitzgerald, Oppenheimer
- Signed / Effective: Jul 14 2026 / same
- Duration / Termination: At will
- Reason: Raise capital for R&D and clinical programs
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.